KCNJ2抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: A549 cell lysate, Primary antibody: P06857(KCNJ2 Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P06857(KCNJ2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The KCNJ2 antibody targets the potassium inwardly rectifying channel subfamily J member 2 (KCNJ2), a protein encoded by the *KCNJ2* gene. KCNJ2. also known as Kir2.1. forms a critical component of inward rectifier potassium channels, which regulate resting membrane potential and cellular excitability in cardiac, skeletal muscle, and neuronal tissues. These channels allow potassium influx more efficiently than efflux, stabilizing repolarization phases of action potentials.

Autoantibodies against KCNJ2 are implicated in autoimmune-related channelopathies. Research links their presence to disorders such as acquired arrhythmias, myopathies, or neurological conditions, where antibodies disrupt Kir2.1 function, leading to altered ion flux and membrane instability. For instance, in some autoimmune encephalitis or myocarditis cases, KCNJ2 antibodies may contribute to electrical dysfunction by blocking or modulating channel activity, resulting in prolonged depolarization or erratic excitability.

Detection methods include immunoassays (e.g., cell-based assays, Western blot) using recombinant Kir2.1 proteins or transfected cells. Clinically, identifying KCNJ2 antibodies aids in diagnosing autoimmune channelopathies, guiding immunosuppressive therapies. However, their pathogenic role and prevalence remain under investigation, with studies often focusing on coexisting autoimmune markers (e.g., anti-SSA/Ro in connective tissue diseases). Further research is needed to clarify their direct contribution to disease mechanisms and therapeutic implications.